U.S. Markets closed

Biotricity Achieves Significant Milestones for Both Fetal/Maternal and Ambulatory Wellness Monitoring Systems

Hospital-based R&D Program Underway and Generating Measurable Clinical Data

REDWOOD CITY, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Biotricity, Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that it has achieved significant progress in their University of Calgary-based R & D program for their latest wellness monitoring systems. Clinical data collection has commenced for both its fetal/maternal and ambulatory adult heart rate variability (HRV) monitoring systems.

Dr. David Liepert, QA/QI and Safety Lead and Director for the University of Calgary Cumming School of Medicine Department of Anesthesia commented, “We could not be more excited to participate in developing both these non-invasive medical-grade ambulatory monitors, utilizing the amazing fidelity and mobility of the Bioflux system. We expect both tools to contribute to better outcomes, lower costs and increased patient satisfaction.”

Appropriate pre-rehabilitation and post-surgical rehabilitation has been shown to save up to $2,000 per patient and per surgery. Today, 89 percent of laboring patients in North America currently receive electronic fetal monitoring using either lower fidelity and less precise sound-based electrodes or higher fidelity fetal scalp electrodes. Trans-vaginal intrauterine pressure monitoring is used in approximately 15 percent of deliveries. Both electrode monitoring and trans-vaginal intrauterine pressure monitoring are invasive techniques that introduce possible trauma, infection, and patient discomfort.

Real-world ambulatory HRV monitoring will facilitate early risk stratification and more responsive patient management. Improved maternal/fetal prenatal and in-labor monitoring will assist caregivers to better control existing maternal conditions such as high blood pressure, diabetes and serious complications like pre-eclampsia. HRV monitoring will also facilitate safer and more comfortable antepartum care, making unforeseeable risks more predictable, manageable and potentially preventable. The U of C/Biotricity program will use actual clinical data to guide the development of efficient data processing and effective displays for both ambulatory adult medical and surgical patients and for non-invasive fetal/maternal prenatal and labor monitoring systems.

Biotricity seeks to facilitate the development of future medical devices that are easy to utilize in either the physician’s office or the patient’s home as well as in acute-care settings. These medical-grade wearables are comfortable and small, and can offer precise remote data collection and more responsive care.

About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
Chris@mccoinsmith.com, 508-429-5988
Richard Smith,
rick@mccoinsmith.com, 978-433-3304

Investor Relations:
Biotricity Inc.
1-800-951-3348
investors@biotricity.com